eprintid: 18939
rev_number: 19
eprint_status: archive
userid: 587
dir: disk0/00/01/89/39
datestamp: 2010-01-07 14:41:25
lastmod: 2015-07-23 09:38:23
status_changed: 2010-01-07 14:41:25
type: article
metadata_visibility: show
item_issues_count: 0
creators_name: Petzold, A.
creators_name: Brassat, D.
creators_name: Mas, P.
creators_name: Rejdak, K.
creators_name: Keir, G.
creators_name: Giovannoni, G.
creators_name: Thompson, E.J.
creators_name: Clanet, M.
creators_id: APETZ95
creators_id: KREJD89
creators_id: GKEIR26
title: Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis
ispublished: pub
subjects: 25900
divisions: F87
keywords: S100B, neurofilament, NfHSMI35 , NOx , surrogate marker, multiple sclerosis, treatment response
note: © Arnold 2004
abstract: BACKGROUND: This study aimed to investigate if treatment response could retrospectively be related to inflammatory or axonal pathology as measured by plasma surrogate markers. METHODS: In this 1-year observational study 30 multiple sclerosis (MS) patients with relapsing-remitting disease were treated with intramuscular IFNbeta-1a or subcutaneous IFNbeta-1b. Responders and nonresponders were defined according to clinical and magnetic resonance imaging criteria. The control group consisted of 14 healthy subjects. Plasma levels of surrogate markers for inflammation (nitric oxide metabolites (NOx)), astrocytic activation (S100B) and axonal damage (NfH(SM135)) were measured using standard assays. RESULTS: There were 11 nonresponders and 19 responders to IFNbeta treatment. Median S100B levels were elevated in a higher proportion of treatment responders (63%, 42.9 pg/mL) compared to nonresponders (18%, 11.7 pg/mL, P < 0.05, Fisher's exact test) and controls (0%, 2 pg/mL, P < 0.001). Levels of NOx were found to be more frequently elevated in nonresponders (72%, 39 microM) compared to healthy controls (0%, 37 microM, P < 0.05). Levels of NfH(SM135) were more frequently elevated in responders (58%, 300 pg/mL, P < 0.001) and nonresponders (72%, 500 pg/mL, P < 0.001) compared to controls (0%, 4.5 pg/mL). CONCLUSION: Patients with relapsing-remitting MS who had surrogate marker supported evidence for astrocytic activation responded more frequently to treatment with IFNbeta.
date: 2004
official_url: http://dx.doi.org/10.1191/1352458504ms1021sr
vfaculties: VFBRS
oa_status: green
language: eng
primo: open
primo_central: open_green
doi: 10.1191/1352458504ms1021sr
lyricists_name: Petzold, A
lyricists_id: APETZ95
full_text_status: public
publication: Multiple Sclerosis
volume: 10
number: 3
pagerange: 281-283
refereed: TRUE
issn: 1352-4585
citation:        Petzold, A.;    Brassat, D.;    Mas, P.;    Rejdak, K.;    Keir, G.;    Giovannoni, G.;    Thompson, E.J.;           Petzold, A.;  Brassat, D.;  Mas, P.;  Rejdak, K.;  Keir, G.;  Giovannoni, G.;  Thompson, E.J.;  Clanet, M.;   - view fewer <#>    (2004)    Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis.                   Multiple Sclerosis , 10  (3)   pp. 281-283.    10.1191/1352458504ms1021sr <https://doi.org/10.1191/1352458504ms1021sr>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/18939/1/18939.pdf